SYNTHETIC LETHALITY AND SEMI-LETHALITY AMONG FUNCTIONALLY RELATED MUTANTS OF DROSOPHILA MELANOGASTER
Open accessAbstract
sex-linked mutant deep orange (dor) of Drosophila melanogaster is Tzonsible for a peculiar type of female sterility: mutant females produce no progeny when crossed to mutant males but yield some offspring (heterozygous daughters) when mated to wild-type males (MERRELL 1947). The effects of this mutant on embryonic development have been extensively studied by COUNCE (1956a) and more recently by HILDRETH and LUCCHESI (1967). In addition to the sterility phene, dor alters the pigmentation of the eyes (which are orange in color) and confers an abnormal spectrum of relative pteridine concentrations. An unusual characteristic of dor is that isoxanthopterin appears to be accumulated by mutant females (COUNCE 1957). During the course of preliminary investigations into the biochemical basis of dor female-sterility, art attempt was made to prevent the accumulation of isoxanthopterin in mutant females by genetic means. This resulted in the discovery of a highly specific synthetic lethal system involving dor and a non-allelic third chromosome mutant, rosy (ry) . The dor-ry system is similar to three other synthetic lethal systems, previously described in D. melanogaster: purpleoid (pd) and Purpleoider (Pdr) (BRIDGES 1922; as cited in BRIDGES and BREHME 1944) ; prune (pn) and Prune-killer (K-pn) ( STURTEVANT 1956) ; and Henna-recessiue-3 (Hnr3) and rosy (ry6) (TAIRA 1960; GOLDBERG, SCHALET and CHOVNICK 1962). A search was undertaken for the purpose of uncovering additional interactions among some of the mutants mentioned above. Since six of the latter affect eye color and/or pteridine levels, a number of other eye color mutants were tested. In addition, the female sterile mutant fused (fu) , similar in many respects to dor (although allowing lethal embryos to develop further than dor embryos (COUNCE 195613) ). was used in <some crosses. The results of these investigations are presented in this paper.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Synthetic genetic interaction screens in yeast show thousands of combinations of individually viable mutations can be jointly lethal, with similar examples in Drosophila and C. elegans.
“Synthetic genetic interaction screens in yeast123,124 have demonstrated that thousands of combinations of individually viable mutations can jointly be lethal, and similar examples have been documented in Drosophila melanogaster and Caenorhabditis elegans125,126.”
From Rare and common variants: twenty arguments (2012) · cites this paper as [125]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
ON ESTIMATING THE RELATION BETWEEN BLOOD GROUP AND DISEASE
Woolf, B. (1955) · Annals of Human Genetics · doi:10.1111/j.1469-1809.1955.tb01348.x · Cited by 2,739 · see citing works
The mutants of drosophila melanogaster
Bridges, C. B., & Brehme, K. S. (1944) · Carnegie Institution of Washington eBooks · Cited by 321 · see citing works
Studies on female-sterility genes inDrosophila melanogaster
Counce, S. J. (1956) · Molecular Genetics and Genomics · doi:10.1007/bf00737163 · Cited by 72 · see citing works
BIOCHEMICAL DIFFERENCES BETWEEN THE MUTANTS ROSY-2 AND MAROON-LIKE OF DROSOPHILA MELANOGASTER
FORREST, H. S., Hanly, E. W., & Lagowski, J. M. (1961) · Genetics · doi:10.1093/genetics/46.11.1455 · Cited by 41 · see citing works
Chovnick, A., Schalet, A., Kernaghan, R. P., & Talsma, J. (1962) · The American Naturalist · doi:10.1086/282236 · Cited by 22 · see citing works
Flagged first, then by citations
Research works printed but not linked: 1
- HapoRN, E., 1955 Letalfactoren in ihrer Bedeutung für Erbpathologie und Genphysiologie der Entwicklung. English translation, 1961, Wiley, N.Y.
Cited by
Sorted by citations
The DNA damage response and cancer therapy
Lord, C. J., & Ashworth, A. (2012) · Nature · doi:10.1038/nature10760 · Cited by 1,843 · see citing works
Targeting the DNA Damage Response in Cancer
O’Connor, M. J. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.10.040 · Cited by 1,551 · see citing works
The Concept of Synthetic Lethality in the Context of Anticancer Therapy
Kaelin, W. G. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1691 · Cited by 1,369 · see citing works
Rare and common variants: twenty arguments
Gibson, G. (2012) · Nature Reviews Genetics · doi:10.1038/nrg3118 · Cited by 1,278 · see citing works
Synthetic lethality and cancer
O’Neil, N. J., Bailey, M. L., & Hieter, P. (2017) · Nature Reviews Genetics · doi:10.1038/nrg.2017.47 · Cited by 658 · see citing works
Scholl, C., Fröhling, S., Dunn, I. F., Schinzel, A. C., Barbie, D. A., Kim, S. Y., Silver, S. J., Tamayo, P., Wadlow, R. C., Ramaswamy, S., et al. (2009) · Cell · doi:10.1016/j.cell.2009.03.017 · Cited by 539 · see citing works
Synthetic Genetic Array Analysis in Saccharomyces cerevisiae
Tong, A. H. Y., & Boone, C. M. (2005) · Humana Press eBooks · doi:10.1385/1-59259-958-3:171 · Cited by 489 · see citing works
Synthetic lethality as an engine for cancer drug target discovery
Huang, A., Garraway, L. A., Ashworth, A., & Weber, B. L. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0046-z · Cited by 470 · see citing works
Genetic Interactions in Cancer Progression and Treatment
Ashworth, A., Lord, C. J., & Reis-Filho, J. S. (2011) · Cell · doi:10.1016/j.cell.2011.03.020 · Cited by 421 · see citing works
Marked for death: Targeting epigenetic changes in cancer
Pfister, S. X., & Ashworth, A. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.256 · Cited by 288 · see citing works
PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications
Zhu, H., Wei, M., Xu, J., Hua, J., Chen, L., Meng, Q., Zhang, Y., Liu, J., Zhang, B., Yu, X., et al. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01167-9 · Cited by 258 · see citing works
Rational Cancer Treatment Combinations: An Urgent Clinical Need
Boshuizen, J., & Peeper, D. S. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.05.031 · Cited by 216 · see citing works
Synthetic Genetic Array (SGA) Analysis in Saccharomyces cerevisiae and Schizosaccharomyces pombe
Baryshnikova, A., Costanzo, M., Dixon, S. J., Vizeacoumar, F. J., Myers, C. L., Andrews, B., & Boone, C. M. (2010) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(10)70007-0 · Cited by 201 · see citing works
Synthetic lethality: exploiting the addiction of cancer to DNA repair
Shaheen, M. F., Allen, C., Nickoloff, J. A., & Hromas, R. (2011) · Blood · doi:10.1182/blood-2011-01-313734 · Cited by 200 · see citing works
Gourley, C., Balmañà, J., Ledermann, J. A., Serra, V., Dent, R. A., Loibl, S., Pujade-Lauraine, É., & Boulton, S. J. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.02050 · Cited by 193 · see citing works
Not just pretty eyes: Drosophila eye-colour mutations and lysosomal delivery
Lloyd, V. K., Ramaswami, M., & Krämer, H. (1998) · Trends in Cell Biology · doi:10.1016/s0962-8924(98)01270-7 · Cited by 165 · see citing works
Drugging the addict: non‐oncogene addiction as a target for cancer therapy
Nagel, R., Semenova, E. A., & Berns, A. J. M. (2016) · EMBO Reports · doi:10.15252/embr.201643030 · Cited by 153 · see citing works
Inbreeding: One word, several meanings, much confusion
Templeton, A. R., & Read, B. (1994) · Birkhäuser Basel eBooks · doi:10.1007/978-3-0348-8510-2_9 · Cited by 152 · see citing works
Targeted cancer therapies based on the inhibition of DNA strand break repair
O’Connor, M. J., Martin, N. M. B., & Smith, G. C. M. (2007) · Oncogene · doi:10.1038/sj.onc.1210879 · Cited by 144 · see citing works
Wu, C., & Ganetzky, B. (1980) · Nature · doi:10.1038/286814a0 · Cited by 145 · see citing works
Genes and networks regulating root anatomy and architecture
Wachsman, G., Sparks, E. E., & Benfey, P. N. (2015) · New Phytologist · doi:10.1111/nph.13469 · Cited by 134 · see citing works
Targeting DNA repair pathway in cancer: Mechanisms and clinical application
Wang, M., Chen, S., & Ao, D. (2021) · MedComm · doi:10.1002/mco2.103 · Cited by 134 · see citing works
Development of synthetic lethality in cancer: molecular and cellular classification
Li, S., Topatana, W., Juengpanich, S., Cao, J., Hu, J., Zhang, B., Ma, D., Cai, X., & Chen, M. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00358-6 · Cited by 117 · see citing works
Exploiting synthetic lethal interactions for targeted cancer therapy
Reinhardt, H. C., Jiang, H., Hemann, M. T., & Yaffe, M. B. (2009) · Cell Cycle · doi:10.4161/cc.8.19.9626 · Cited by 110 · see citing works
Searching for synthetic lethality in cancer
Brough, R., Frankum, J. R., Costa-Cabral, S., Lord, C. J., & Ashworth, A. (2011) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2010.10.009 · Cited by 104 · see citing works
Synthetic lethal approaches to breast cancer therapy
Rehman, F. L., Lord, C. J., & Ashworth, A. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.172 · Cited by 102 · see citing works
Targeting DNA repair in cancer: current state and novel approaches
Klinakis, A., Karagiannis, D., & Rampias, T. N. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03299-8 · Cited by 105 · see citing works
Synthetic lethality: a framework for the development of wiser cancer therapeutics
Kaelin, W. G. (2009) · Genome Medicine · doi:10.1186/gm99 · Cited by 101 · see citing works
ATM-depletion in breast cancer cells confers sensitivity to PARP inhibition
Montani, M. S. G., Prodosmo, A., Stagni, V., Merli, D., Monteonofrio, L., Gatti, V., Gentileschi, M. P., Barilà, D., & Soddu, S. (2013) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-32-95 · Cited by 94 · see citing works
Belmontes, B., Slemmons, K. K., Su, C., Liu, S., Policheni, A. N., Moriguchi, J., Tan, H. L. E., Xie, F., Aiello, D. A., Yang, Y., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0887 · Cited by 89 · see citing works
Morel, D., Almouzni, G., Soria, J., & Postel-Vinay, S. C. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw552 · Cited by 84 · see citing works
Homyk, T., & Emerson, C. P. (1988) · Genetics · doi:10.1093/genetics/119.1.105 · Cited by 81 · see citing works
Von Hippel–Lindau protein signalling in clear cell renal cell carcinoma
Liao, C., Hu, L., & Zhang, Q. H. (2024) · Nature Reviews Urology · doi:10.1038/s41585-024-00876-w · Cited by 83 · see citing works
Development of Synthetic Lethality Anticancer Therapeutics
Fang, B. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500415t · Cited by 71 · see citing works
BRCAness: a deeper insight into basal-like breast tumors
Summa, S. D., Pinto, R., Sambiasi, D., Petriella, D., Paradiso, V., Paradiso, A., & Tommasi, S. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt306 · Cited by 71 · see citing works
Taking on Challenging Targets: Making MYC Druggable
Horiuchi, D., Anderton, B. N., & Goga, A. (2014) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2014.34.e497 · Cited by 67 · see citing works
Exploiting epigenetic vulnerabilities for cancer therapeutics
Mair, B., Kubicek, S., & Nijman, S. M. B. (2014) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2014.01.001 · Cited by 66 · see citing works
DNA repair as a shared hallmark in cancer and ageing
Clarke, T. L., & Mostoslavsky, R. (2022) · Molecular Oncology · doi:10.1002/1878-0261.13285 · Cited by 68 · see citing works
Metabolic synthetic lethality in cancer therapy
Zecchini, V. R., & Frezza, C. (2016) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2016.12.003 · Cited by 62 · see citing works
Tucker, C. L., & Fields, S. (2003) · Nature Genetics · doi:10.1038/ng1103-204 · Cited by 60 · see citing works
Exploiting the balance between life and death: Targeted cancer therapy and “oncogenic shock”
Sharma, S. V., & Settleman, J. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.03.001 · Cited by 58 · see citing works
An intermittent approach for cancer chemoprevention
Wu, X., & Lippman, S. M. (2011) · Nature reviews. Cancer · doi:10.1038/nrc3167 · Cited by 58 · see citing works
GENETIC FINE STRUCTURE OF THE Y CHROMOSOME OF DROSOPHILA HYDEI
Hackstein, J. H. P., Leoncini, O., Beck, H., Peelen, G. O. H., & Hennig, W. (1982) · Genetics · doi:10.1093/genetics/101.2.257 · Cited by 58 · see citing works
Bagnolini, G., Milano, D., Manerba, M., Schipani, F., Ortega, J. A., Gioia, D., Falchi, F., Balboni, A., Farabegoli, F., Franco, F., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01526 · Cited by 57 · see citing works
Chemoprevention – History and general principles
Wu, X., Patterson, S. L., & Hawk, E. T. (2011) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2011.10.012 · Cited by 57 · see citing works
The Isolation of Biological Rhythm Mutations on the Autosomes of Drosophila melanogaster
Jackson, F. R. (1983) · Journal of Neurogenetics · doi:10.3109/01677068309107068 · Cited by 56 · see citing works
Ehrenhöfer-Wölfer, K., Puchner, T., Schwarz, C., Rippka, J., Blaha-Ostermann, S., Strobl, U., Hörmann, A., Bader, G., Kornigg, S., Zahn, S. K., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-48152-x · Cited by 51 · see citing works
Synthetic Lethality in Ovarian Cancer
Chandrasekaran, A., & Elias, K. M. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0500 · Cited by 41 · see citing works
Mereniuk, T. R., Maranchuk, R. A., Schindler, A., Penner-Chea, J., Freschauf, G. K., Hegazy, S. A., Lai, R. L., Foley, E., & Weinfeld, M. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0939 · Cited by 40 · see citing works
Synthetic Lethal Vulnerabilities of Cancer
de la Cruz, F. F., Gapp, B. V., & Nijman, S. M. B. (2014) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010814-124511 · Cited by 39 · see citing works
Therapeutic targeting and patient selection for cancers with homologous recombination defects
Talens, F., Jalving, M., Gietema, J. A., & van Vugt, M. A. T. M. (2017) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2017.1322061 · Cited by 38 · see citing works
Circadian clock: Time for novel anticancer strategies?
Ercolani, L., Ferrari, A., Mei, C. D., Parodi, C., Wade, M. R., & Grimaldi, B. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.08.008 · Cited by 35 · see citing works
Synthetic lethality in lung cancer and translation to clinical therapies
Leung, A. W. Y., de Silva, T., Bally, M. B., & Lockwood, W. W. (2016) · Molecular Cancer · doi:10.1186/s12943-016-0546-y · Cited by 35 · see citing works
Eckardt, J., Stasik, S., Röllig, C., Sauer, T., Scholl, S., Hochhaus, A., Crysandt, M. M., Brümmendorf, T. H., Naumann, R., Steffen, B., et al. (2023) · Blood Cancer Journal · doi:10.1038/s41408-023-00790-1 · Cited by 37 · see citing works
Peng, S., Long, M., Chen, Q.-S., Yin, Z., Zeng, C., Zhang, W., Wen, Q., Zhang, X., Ke, W., & Wu, Y. (2025) · Cell Death Discovery · doi:10.1038/s41420-025-02418-8 · Cited by 33 · see citing works
Targeting protein–protein interactions in the DNA damage response pathways for cancer chemotherapy
McPherson, K. S., & Korzhnev, D. M. (2021) · RSC Chemical Biology · doi:10.1039/d1cb00101a · Cited by 33 · see citing works
Kranthi, T., Rao, S. B., & Manimaran, P. (2013) · Molecular BioSystems · doi:10.1039/c3mb25589a · Cited by 29 · see citing works
ESM1 mediates NGFR-induced invasion and metastasis in murine oral squamous cell carcinoma
Chen, C., Shin, J. H., Eggold, J. T., Chung, M. K., Zhang, L. H., Lee, J., & Sunwoo, J. B. (2016) · Oncotarget · doi:10.18632/oncotarget.12210 · Cited by 29 · see citing works
The development of eggs produced by the female‐sterile mutant almondex of Drosophila melanogaster
Shannon, M. P. (1973) · Journal of Experimental Zoology · doi:10.1002/jez.1401830312 · Cited by 29 · see citing works
Clinical prospects of WRN inhibition as a treatment for MSI tumours
Morales-Juarez, D. A., & Jackson, S. P. (2022) · npj Precision Oncology · doi:10.1038/s41698-022-00319-y · Cited by 28 · see citing works
Synthetic lethal gene pairs: Experimental approaches and predictive models
Tang, S., Gökbağ, B., Fan, K., Shao, S., Huo, Y., Wu, X., Cheng, L., & Li, L. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.961611 · Cited by 27 · see citing works
Abbosh, P. H., & Plimack, E. R. (2018) · Bladder Cancer · doi:10.3233/blc-170129 · Cited by 26 · see citing works
Cyclin-dependent kinases-based synthetic lethality: Evidence, concept, and strategy
Li, K., You, J., Wu, Q., Meng, W., He, Q., Yang, B. R., Zhu, C., & Cao, J. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.01.002 · Cited by 25 · see citing works
Parallel universes of Black Six biology
Kraev, A. S. (2014) · Biology Direct · doi:10.1186/1745-6150-9-18 · Cited by 25 · see citing works
Lachance, J., & True, J. (2010) · Evolution · doi:10.1111/j.1558-5646.2010.01028.x · Cited by 24 · see citing works
Huang, S., Ren, X., Wang, L., Zhang, L., & Wu, X. (2011) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-10-0235 · Cited by 24 · see citing works
Bastos, I. F., Rebelo, S., & Silva, V. L. M. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116045 · Cited by 22 · see citing works
Lloyd, V. K., Sinclair, D. A., Alperyn, M., & Grigliatti, T. A. (2002) · Genome · doi:10.1139/g01-139 · Cited by 19 · see citing works
Węsierska‐Gądek, J., & Składanowski, A. (2011) · Future Medicinal Chemistry · doi:10.4155/fmc.11.175 · Cited by 18 · see citing works
Isolation and characterization of the prune locus of Drosophila melanogaster.
Teng, D. H., Bender, L. B., Garrett-Engele, C. M., Tsubota, S. I., & Venkatesh, T. (1991) · Genetics · doi:10.1093/genetics/128.2.373 · Cited by 18 · see citing works
Crespan, E., Garbelli, A., Amoroso, A., & Maga, G. (2011) · Molecules · doi:10.3390/molecules16097994 · Cited by 17 · see citing works
Mauro, A. D., Berretta, M., Santorsola, M., Ferrara, G., Picone, C., Savarese, G., & Ottaiano, A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26167723 · Cited by 16 · see citing works
Exploration of Synthetic Lethal Interactions as Cancer Drug Targets
Kuiken, H. J., & Beijersbergen, R. L. (2010) · Future Oncology · doi:10.2217/fon.10.131 · Cited by 16 · see citing works
Fine tuning chemotherapy to match BRCA1 status
Price, M. L., & Monteiro, Á. N. A. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.05.015 · Cited by 16 · see citing works
Application of the concept synthetic lethality toward anticancer therapy: A promise fulfilled?
Canaani, D. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.08.019 · Cited by 15 · see citing works
Natural products targeting cancer cell dependency
Shi, C., Yang, E. J., Tao, S., Ren, G., Mou, P. K., & Shim, J. S. (2021) · The Journal of Antibiotics · doi:10.1038/s41429-021-00438-x · Cited by 14 · see citing works
DNA Damage Response Pathways and Cancer
Ford, J. M., & Kastan, M. B. (2014) · Elsevier eBooks · doi:10.1016/b978-1-4557-2865-7.00010-2 · Cited by 14 · see citing works
Lethal interactions of theeye-goneandeyelessmutants inDrosophila melanogaster
Hunt, D. M. (1970) · Genetics Research · doi:10.1017/s0016672300001348 · Cited by 14 · see citing works
The action of the geneprune (pn)inDrosophila melanogaster
Lifschytz, E., & Falk, R. (1969) · Genetics Research · doi:10.1017/s0016672300001841 · Cited by 14 · see citing works
Throwing a monkey wrench in the motor: Targeting DExH/D box proteins with small molecule inhibitors
Cencic, R., & Pelletier, J. (2013) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2013.01.008 · Cited by 13 · see citing works
Targeting “undruggable” c-Myc protein by synthetic lethality
Wang, C., Fang, H., Zhang, J., & Gu, Y. (2021) · Frontiers of Medicine · doi:10.1007/s11684-020-0780-y · Cited by 13 · see citing works
Jiang, Z., Li, X., Xiao, Z., Gan, W., Zhang, X., Zhang, Y., Wang, W., Qinzhi, E., Huang, Y., Shi, Q., et al. (2025) · Cell Death Discovery · doi:10.1038/s41420-025-02545-2 · Cited by 12 · see citing works
Advancements and Obstacles of PARP Inhibitors in Gastric Cancer
Chen, H., Hu, Y., Zhuang, Z., Wang, D., Ye, Z., Ji, J., & Cheng, X. (2023) · Cancers · doi:10.3390/cancers15215114 · Cited by 12 · see citing works
The Population Genetics of X–Autosome Synthetic Lethals and Steriles
Lachance, J., Johnson, N., & True, J. (2011) · Genetics · doi:10.1534/genetics.111.131276 · Cited by 12 · see citing works
Exploiting replication stress for synthetic lethality in MYC-driven cancers
Zhang, Y. (2025) · American Journal of Cancer Research · doi:10.62347/rtvx8866 · Cited by 10 · see citing works
The role of Vps4 in cancer development
Huang, L. J., Zhan, S. T., Pan, Y., Bao, W., & Yang, Y. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1203359 · Cited by 10 · see citing works
Gao, K., Zhu, S., Shao, Q., Qi, Y., Zhang, C., Li, X., Guo, J., Wu, G., & Jiang, H. (2023) · Translational Oncology · doi:10.1016/j.tranon.2023.101708 · Cited by 10 · see citing works
Co-lethality studied as an asset against viral drug escape: the HIV protease case
Brouillet, S., Valère, T., Ollivier, E., Marsan, L., & Vanet, A. (2010) · Biology Direct · doi:10.1186/1745-6150-5-40 · Cited by 10 · see citing works
Functional genomics to explore cancer cell vulnerabilities
Kahle, K. T., Kozono, D., Ng, K., Hsieh, G., Zinn, P. O., Nitta, M., & Chen, C. C. (2009) · Neurosurgical FOCUS · doi:10.3171/2009.10.focus09212 · Cited by 9 · see citing works
The role of PARP inhibitors in gastrointestinal cancers
Hanna, D., Chopra, N., Hochhauser, D., & Khan, K. H. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103621 · Cited by 9 · see citing works
DNA Damage Response Pathways and Cancer
Ford, J. M., & Kastan, M. B. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-47674-4.00011-6 · Cited by 9 · see citing works
Inhibition of RNA synthesis in Drosophila embryos by isoxanthopterin
Puckett, L., & Snyder, L. A. (1975) · Biochemical Genetics · doi:10.1007/bf00486001 · Cited by 9 · see citing works
ASTER: A Method to Predict Clinically Relevant Synthetic Lethal Genetic Interactions
Liany, H., Jayagopal, A., Huang, D., Lim, J. Q., Nur Izzah, N. B. H., Jeyasekharan, A. D. D., Ong, C. K., & Rajan, V. (2024) · IEEE Journal of Biomedical and Health Informatics · doi:10.1109/jbhi.2024.3354776 · Cited by 8 · see citing works
Poly (ADP-ribose) polymerase inhibitor efficacy in head and neck cancer
Schaule, J., Geeleher, P., Zuo, Z., Weichselbaum, R. R., Vokes, E. E., Fetscher, S., & Seiwert, T. Y. (2014) · Oral Oncology · doi:10.1016/j.oraloncology.2014.06.004 · Cited by 8 · see citing works
Challenges in Cancer Molecular Targets and Therapeutics
Wang, Y., & Giaccone, G. (2011) · Frontiers in Oncology · doi:10.3389/fonc.2011.00004 · Cited by 8 · see citing works
Dysfunctional β-cell longevity in diabetes relies on energy conservation and positive epistasis
Raval, K., Jamshidi, N., Seyran, B., Salwiński, Ł., Pillai, R. K., Yang, L., Ma, F., Pellegrini, M. A., Shin, J., Yang, X., et al. (2024) · Life Science Alliance · doi:10.26508/lsa.202402743 · Cited by 8 · see citing works
Targeting DNA Damage Repair Pathways Beyond PARP Inhibition
Merry, E., & Gourley, C. (2025) · Targeted Oncology · doi:10.1007/s11523-025-01183-z · Cited by 6 · see citing works
Bueno, R., & Mar, J. C. (2017) · Methods · doi:10.1016/j.ymeth.2017.07.021 · Cited by 6 · see citing works
Cancer biology functional genomics: From small RNAs to big dreams
Rajan, S. S., Ludwig, K. R., Hall, K. L., Jones, T. L., & Caplen, N. J. (2020) · Molecular Carcinogenesis · doi:10.1002/mc.23260 · Cited by 6 · see citing works
ASTER: A Method to Predict Clinically Actionable Synthetic Lethal Genetic InteractionsPreprint
Liany, H., Jeyasekharan, A. D. D., & Rajan, V. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.10.27.356717 · Cited by 6 · see citing works
- Authors
- Lucchesi, J. C.
- Corresponding author
- Lucchesi, John C
- ORCID
- Lucchesi, John C
- Venue
- Genetics
- Publisher
- Oxford University Press (OUP)
- Published
- 1968-05-01
- Volume
- 59
- Issue
- 1
- Pages
- 37-44
- ISSN
- 0016-6731 (ISSN-L)
- 1943-2631
- OpenAlex
- W2123596976
- Cited by
- 139
- References
- 5
- Citations by year
- 2026: 5 · 2025: 11 · 2024: 6 · 2023: 7 · 2022: 10 · 2021: 8 · 2020: 8 · 2019: 4 · 2018: 1 · 2017: 5 · 2016: 7 · 2015: 7 · 2014: 7 · 2013: 7 · 2012: 4
- FWCI
- 0.74
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- Genetics (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurobiology and Insect Physiology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Developmental Biology and Gene Regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Biochemical and Molecular Research
- Keywords
- synthetic lethality, female sterility, isoxanthopterin, pteridines, eye color mutants, Drosophila melanogaster, third chromosome
- MeSH terms
- Crosses, Genetic, Drosophila, Female, Genes, Lethal, Infertility, Female, Male, Mutation, Pigmentation, Pteridines
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review